x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAA-001229
| Product Information | |
|---|---|
| Product Name | Senescence β-Galactosidase Activity Assay Kit (Fluorescence, Flow Cytometry) |
| Description | The Senescence β-Galactosidase Activity Assay Kit (Fluorescence, Flow Cytometry) allows the quantitative measure of senescence-associated β-galactosidase activity in living cells via flow cytometry using a cell permeable fluorogenic substrate, which becomes fluorescent upon hydrolysis by β-galactosidase. The fluorescent molecule is optimally excited at 490 nm (blue laser) and peak emission occurs at 514 nm (usually FL1). Each kit contains sufficient quantities of reagents to perform up to 100 assays. |
| Component | Bafilomycin A1; SA-β-Gal Fluorescent Substrate |
| Target Information | |
|---|---|
| Target Name | lacZ |
| UniProt No. | P00722 |
| Gene ID | 945006 |
| Target Description | Limited capacity to replicate is a defining characteristic of most normal cells and culminates in senescence, an arrested state in which the cell remains viable. Senescent cells are not stimulated to divide by serum or passage in culture, and senescence invokes a specific cell cycle profile that differs from most damage-induced arrest processes or contact inhibition. An enlarged cell size, expression of pH-dependent β-galactosidase activity, and an altered pattern of gene expression further characterize senescent cells. |
| Alternative Names | Lactase; β-gal |
| Shipping & Storage | |
|---|---|
| Sipping | Shipping on dry ice. |
| Storage | Store at -20°C. Please refer to protocols. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
